Stents Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Coronary Stents, Peripheral Stents, Stent-Related Implants, Biliary Stents, Carotid Stents, and Neurovascular Stents), By Material (Metallic, Polymeric, and Natural), and Region Forecast 2019-2030   

Stents Market size was valued at US$ 8.5 billion in 2023 and is poised to grow at a CAGR of 4.1% from 2024-2030. The increase in prevalence of chronic diseases and presence of large number of players in the market developing innovative technologies and rising advances in the field of interventional cardiology coupled with the progress of minimally invasive techniques. Moreover, growing geriatric population and improved healthcare infrastructure fuels the growth of the market.

However, high cost of treatment associated with stent implants and stringent regulatory approval process hinders the growth of the market. Rising aging population and consumer awareness coupled with healthcare expenditure and favorable government policies and modernization of healthcare infrastructure fuels the growth of the market over the forecasted period.

Moreover, approval of new products into the market is forecasted to grow at a significant CAGR over the forecasted years. Americas accounted for larger revenue share in global market with significant CAGR owing to presence of number of interventional cardiologists in the region and high adoption towards advanced technology, growing economy and increasing prevalence of chronic disorders coupled with rise in acceptance of medicinal implants drives the growth of the market. Europe and Asia Pacific expected to be the faster growing region in market over the forecast period. Market players are focusing on the approvals for the novel products and strategic collaborations to strengthen their position into the market.

Stents Market Key Developments

• For instance, in 2016, the FDA approved a new type of stent made of a special polymer that eventually dissolves into the body. This new stent releases a drug called everolimus, which limits the growth of scar tissue that can re-block the coronary artery.